J. Mark Gergen's Insider Trades & SAST Disclosures
J. Mark Gergen's most recent trade in Poseida Therapeutics Inc was a trade of 636,726 Common Stock done . Disclosure was reported to the exchange on Jan. 8, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern J. Mark Gergen.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | 08 Jan 2025 | 636,726 | 0 | - | - | Common Stock | ||
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 518,500 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 364,060 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 342,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 240,721 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 172,600 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 75,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 48,115 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.60 per share. | 02 Jan 2025 | 23,313 | 630,726 | - | 9.6 | 223,805 | Common Stock |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 30,000 | 96,372 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 9.46 per share. | 10 Dec 2024 | 30,000 | 651,291 | - | 9.5 | 283,866 | Common Stock |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.78 per share. | 10 Dec 2024 | 30,000 | 681,291 | - | 2.8 | 83,430 | Common Stock |
| Poseida Therapeutics Inc | Mark Gergen J. | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2024 | 30,000 | 126,372 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | J. Mark Gergen | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 9.27 per share. | 26 Nov 2024 | 30,000 | 651,291 | - | 9.3 | 278,100 | Common Stock |
| Poseida Therapeutics Inc | J. Gergen Mark | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.78 per share. | 26 Nov 2024 | 30,000 | 681,291 | - | 2.8 | 83,430 | Common Stock |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 01 Mar 2024 | 34,157 | 651,291 | - | 4.1 | 141,068 | Common Stock |
| Poseida Therapeutics Inc | J. Gergen Mark | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.41 per share. | 01 Feb 2024 | 47,162 | 685,448 | - | 3.4 | 160,822 | Common Stock |
| Poseida Therapeutics Inc | Gergen Mark J. | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 172,600 | 172,600 | - | - | Stock Option (Right to buy) | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 125,000 | 732,610 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 364,060 | 364,060 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 269,586 | 601,610 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.00 per share. | 01 Feb 2023 | 31,819 | 330,314 | - | 7 | 222,733 | Common Stock |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 518,500 | 518,500 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 357,200 | 357,200 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 342,000 | 342,000 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Mark J. Gergen | Director, President and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2020 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges